Swiss stocks - Factors to watch on May 2 ZURICH/BERLIN, May 2 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: CREDIT SUISSE South Korea's financial authorities have notified Credit Suisse AG it could face 50 billion won ($36.32 million) in fines over allegations it breached short-selling rules, South Korea's Chosun Ilbo daily reported on Thursday, citing industry sources.

EUROPE RESEARCH ROUNDUP-Adidas, HSBC, Renishaw May 1 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adidas, HSBC and Renishaw on Wednesday. HIGHLIGHTS * Adidas AG ADSGn.DE : Wedbush raises target price to EUR 233 from EUR 200 * Darktrace DARK.L : HSBC raises target price to 620p from 540p * Essity AB (Publ) ESSITYb.ST : HSBC resumes with buy rating; price target SEK 330 * HSBC HSBA.L : Berenberg raises target price to 830p from 80

CORRECTED-BUZZ-Dental implant maker Straumann slumps on softer U.S. performance Corrects name and brokerage of the analyst in 2nd and 4th bullets ** Swiss implant maker Straumann STMN.S slumps around 9% after softer performance in North America, its second largest region, overshadows strong Q1 growth in Asia Pacific ** Q1 North America revenues fell 2.3%, which Stifel Europe analyst Daniel Jelovcan says may have taken many by surprise, as most U.S.

UPDATE 2-Straumann shares slip on slowing US dental implant demand Shares down 10.5% at 1046 GMT Organic growth slows in N.America and EMEA CEO says high interest rates hit US patient traffic Q1 organic sales growth 15.1%, with 82% jump in APAC Recasts with share reaction, CEO comments in paragraphs 2-4 By Mateusz Dobrzyniewski and Marleen Kaesebier April 30 (Reuters) - Shares in Swiss dental implants maker Straumann STMN.S fell more than 10% on Tuesday, as slower U.S.

Dental implants maker Straumann posts 15% organic sales growth for Q1 April 30 (Reuters) - Swiss dental implants maker Straumann STMN.S reported 15.1% organic sales growth for the first quarter on Tuesday, driven by high demand for its premium implants across its markets. The company, which specialises in tooth replacement and orthodontic solutions, reported revenue of 643.8 million Swiss francs ($706.5 million) in the first three months of 2024, up from 596 million francs a year earlier.